Rexahn Pharmaceuticals Company Profile (NYSE:RNN)

Analyst Ratings

Consensus Ratings for Rexahn Pharmaceuticals (NYSE:RNN) (?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Rexahn Pharmaceuticals (NYSE:RNN)
Show:
No equities research coverage for this company has been tracked by MarketBeat.com

Earnings

Earnings History for Rexahn Pharmaceuticals (NYSE:RNN)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Rexahn Pharmaceuticals (NYSE:RNN)
No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Rexahn Pharmaceuticals (NYSE:RNN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Rexahn Pharmaceuticals (NYSE:RNN)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Latest Headlines for Rexahn Pharmaceuticals (NYSE:RNN)
DateHeadline
06/29/16 08:56 AMWhy Investors Love These Biotech's Stocks? - Cellectar Biosciences, Xenoport, Rexahn Pharma, and Tesaro
05/24/16 09:15 AMRexahn Pharmaceuticals Inc.: Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology (ASCO ... - The Wall Street Transcript - Rexahn Pharmaceuticals Inc.: Rexahn Pharmaceuticals to Present at the American Society of Clinical Oncology (ASCO ...The Wall Street TranscriptROCKVILLE, Md., May 23, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of cancer, announced today that it will present ...and more »
05/23/16 10:29 AMNotable movements of HC Stocks: Prima BioMed Ltd (ADR) (NASDAQ:PBMD), Rexahn Pharmaceuticals, Inc ... - share market updates (press release) - share market updates (press release)Notable movements of HC Stocks: Prima BioMed Ltd (ADR) (NASDAQ:PBMD), Rexahn Pharmaceuticals, Inc ...share market updates (press release)Shares of Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) ended Friday session in green amid volatile trading. The shares closed up +0.007 points or 2.45% at $0.272 with 548,281.00 shares getting traded. Post opening the session at $0.26, the shares hit ...and more »
05/20/16 05:29 PMRevenue Update on Rexahn Pharmaceuticals(NYSEMKT:RNN) - Trade Calls - Revenue Update on Rexahn Pharmaceuticals(NYSEMKT:RNN)Trade CallsRexahn Pharmaceuticals Inc. is a clinical stage biopharmaceutical company dedicated to the discovery development and commercialization of treatments for cancer and other medical needs. The Company has three clinical stage drug candidates in active ...and more »
05/19/16 08:20 AMRexahn Drugs Deal a Death Blow to Solid Tumor Cancer -
05/16/16 10:30 AMHC Stocks Buzzer: Rexahn Pharmaceuticals (RNN), Aegerion Pharmaceuticals (AEGR), Electromed (ELMD) - share market updates (press release) - HC Stocks Buzzer: Rexahn Pharmaceuticals (RNN), Aegerion Pharmaceuticals (AEGR), Electromed (ELMD)share market updates (press release)Shares of Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) closed at $0.260 with 380,816.00 shares getting traded. Post opening the session at $0.26, the shares hit an intraday low of $0.26 and an intraday high of $0.28 and the price vacillated in this range ...and more »
05/11/16 11:05 PMRexahn Pharmaceuticals, Inc. (RNN) Forecasted to Earn FY2019 Earnings of $0.08 Per Share - Washington News Wire - Rexahn Pharmaceuticals, Inc. (RNN) Forecasted to Earn FY2019 Earnings of $0.08 Per ShareWashington News WireRexahn Pharmaceuticals logo Rexahn Pharmaceuticals, Inc. (AMEX:RNN) – FBR & Co. decreased their FY2019 earnings per share estimates for Rexahn Pharmaceuticals in a report released on Tuesday, according to Zacks Investment Research. FBR & Co.
05/11/16 04:02 AMRexahn Pharmaceuticals, Inc. (RNN) Short Interest Down 24.7% in April - Washington News Wire - Washington News WireRexahn Pharmaceuticals, Inc. (RNN) Short Interest Down 24.7% in AprilWashington News WireRexahn Pharmaceuticals logo Rexahn Pharmaceuticals, Inc. (NYSE:RNN) was the recipient of a significant decrease in short interest during the month of April. As of April 29th, there was short interest totalling 777,327 shares, a decrease of 24.7% from ...and more »
05/09/16 05:42 PMStock's Price Moves: Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) , Carbylan Therapeutics, Inc. (NASDAQ:CBYL) - Street Updates - Stock's Price Moves: Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) , Carbylan Therapeutics, Inc. (NASDAQ:CBYL)Street UpdatesOn 5/6/2016, Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) ended trading session lower at $0.2765 with -1.2500%. The company traded a volume of 552.35 thousand shares as comparison to average volume of 415.36 thousand shares. During the 52 ...and more »
05/08/16 03:31 AMRexahn Pharmaceuticals Incorporated (NYSEMKT:RNN) Shorted Shares Decreased By 13.61% - B.O.D.Y Confidential - Rexahn Pharmaceuticals Incorporated (NYSEMKT:RNN) Shorted Shares Decreased By 13.61%B.O.D.Y ConfidentialThe short interest to Rexahn Pharmaceuticals Incorporated's float is 0.64%. The stock decreased 1.25% or $0.004 on May 6, hitting $0.276. About 552,346 shares traded hands or 19.48% up from the average. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) ...
05/06/16 03:31 PMREXAHN PHARMACEUTICALS, INC. Files SEC form 10-Q, Quarterly Report -
05/05/16 11:15 PMBroker Outlook For Rexahn Pharmaceuticals, Inc. (RNN) - Share Trading News - Broker Outlook For Rexahn Pharmaceuticals, Inc. (RNN)Share Trading NewsThe Company also has a drug candidate RX-21101, an N-(2-Hydroxypropyl) methacrylamide-docetaxel-folate, in pre-clinical development. The Company is working on research technologies, including multi-target aimed ligands platform and nano-based ...Analysts Set $2.42 Target Price for Rexahn Pharmaceuticals, Inc. (NYSE:RNN)Web Breaking Newsall 2 news articles »
05/04/16 05:47 PMNotable Stocks Preview: Amicus Therapeutics, Inc. (NASDAQ:FOLD) , Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) - Street Updates - Notable Stocks Preview: Amicus Therapeutics, Inc. (NASDAQ:FOLD) , Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN)Street UpdatesOn 5/3/2016, Amicus Therapeutics, Inc. (NASDAQ:FOLD) ended trading session lower at $7.07 with -6.11%. The company traded a volume of 1.75 million shares as comparison to average volume of 2.65 million shares. During the 52 –week period, the stock's ...and more »
05/02/16 06:07 PMBroker Outlook For The Week Ahead: Rexahn Pharmaceuticals, Inc. (RNN) - Share Trading News - Broker Outlook For The Week Ahead: Rexahn Pharmaceuticals, Inc. (RNN)Share Trading News03/24/2014 – Brinson Patrick began new coverage on Rexahn Pharmaceuticals, Inc. giving the company a “outperform” rating. The share price of Rexahn Pharmaceuticals, Inc. (RNN) was down -1.15% during the last trading session, with a day high of 0.31.and more »
04/28/16 11:18 PMLet Volatility Power Your Micro-Cap Biotechs - There's trepidation around that on investor fronts. TLSR: Could we talk about some stocks, please? JP: I have Rexahn Pharmaceuticals Inc. (RNN:NYSE.MKT) rated Buy. It has three interesting drugs right now. Supinoxin (RX-5902), a phosphorylated p68 ...
04/28/16 04:22 AMEarnings Trends of the Stock: Rexahn Pharmaceuticals (NYSEMKT:RNN) - News Oracle - News OracleEarnings Trends of the Stock: Rexahn Pharmaceuticals (NYSEMKT:RNN)News OracleLast Trade: The Company rose 5.08% and finished at $0.33. The daily volume was measured at 1.78 million shares. The 52-week high of the share price is $0.77 and the 52-week low is $0.26. The company has a market cap of $70.20 million. Its latest ...Analyst Coverage: Rexahn Pharmaceuticals, Inc. (RNN)Risers & FallersRexahn Pharmaceuticals, Inc. (RNN) Sees Significant Drop in Short InterestWeb Breaking Newsall 3 news articles »
04/27/16 06:01 PMAnalyst Coverage: Rexahn Pharmaceuticals, Inc. (RNN) - Risers & Fallers - News OracleAnalyst Coverage: Rexahn Pharmaceuticals, Inc. (RNN)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Rexahn Pharmaceuticals, Inc. (RNN). The latest broker reports which are currently outstanding on Wednesday 27th of April state 0 analysts have a rating of “strong buy”, ...Earnings Trends of the Stock: Rexahn Pharmaceuticals (NYSEMKT:RNN)News OracleRexahn Pharmaceuticals, Inc. (RNN) Sees Significant Drop in Short InterestWeb Breaking Newsall 3 news articles »
04/25/16 06:45 PMStock's Buzz on These Trending Stocks BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Rexahn Pharmaceuticals, Inc ... - The Point Review - The Point ReviewStock's Buzz on These Trending Stocks BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX), Rexahn Pharmaceuticals, Inc ...The Point ReviewShares of Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) rose 5.71% to $0.333 at 12:34PM EDT. The stock exchanged hands of 1.12 million shares recently versus average trading capacity of 370,409 shares. However recently the stock touch highest ...and more »
04/24/16 06:27 PMRexahn Pharmaceuticals, Inc. (RNN) Broker Price Targets For The Coming Week - Share Trading News - Rexahn Pharmaceuticals, Inc. (RNN) Broker Price Targets For The Coming WeekShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Rexahn Pharmaceuticals, Inc. (RNN). The latest reports which are currently in issue on Sunday 24th of April state 0 analysts have a rating of “strong buy”, 0 analysts ...and more »
04/21/16 06:06 PMRexahn Pharmaceuticals, Inc. (RNN) - Broker Update - Risers & Fallers - Rexahn Pharmaceuticals, Inc. (RNN) - Broker UpdateRisers & FallersThe Company also has a drug candidate RX-21101, an N-(2-Hydroxypropyl) methacrylamide-docetaxel-folate, in pre-clinical development. The Company is working on research technologies, including multi-target aimed ligands platform and nano-based ...
04/20/16 06:00 PMBroker Roundup For Rexahn Pharmaceuticals, Inc. (RNN) - Share Trading News - Broker Roundup For Rexahn Pharmaceuticals, Inc. (RNN)Share Trading NewsThe share price of Rexahn Pharmaceuticals, Inc. (RNN) was down -0.09% during the last trading session, with a day high of 0.34. 259794 shares were traded on Rexahn Pharmaceuticals, Inc.'s last session. The stock's 50 day moving average is 0.34 and its ...and more »
04/20/16 06:00 PMStock Update (NYSEMKT:RNN): Rexahn Pharmaceuticals, Inc. Presents Clinical Trial Results for Archexin® at the ... - Smarter Analyst - Stock Update (NYSEMKT:RNN): Rexahn Pharmaceuticals, Inc. Presents Clinical Trial Results for Archexin® at the ...Smarter AnalystRexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of cancer, announced today that final data from the dose-escalation segment (Stage 1) of a Phase Ib/IIa ...Rexahn Pharmaceuticals Says Clinical Data Suggest Dose, Time Dependent Clinical Benefit of Archexin (NYSEMKT ...Sonoran Weekly Reviewall 2 news articles »
04/13/16 05:59 PMHere is What Institutional Investors Think About Rexahn Pharmaceuticals Inc (NYSEMKT:RNN) - Stock Caller - Here is What Institutional Investors Think About Rexahn Pharmaceuticals Inc (NYSEMKT:RNN)Stock CallerRexahn Pharmaceuticals Inc (NYSEMKT:RNN) institutional sentiment increased to 1.1 in Q3 2015. Its up 0.30, from 0.8 in 2015Q2. The ratio is positive, as 8 hedge funds increased or opened new holdings, while 10 cut down and sold stakes in Rexahn ...Rexahn Pharmaceuticals, Inc. (RNN) Latest Broker CoverageRisers & FallersRexahn Pharmaceuticals to Present at the 2016 American Association for Cancer Research Annual MeetingStockhouseall 3 news articles »
04/13/16 10:07 AMRexahn Pharmaceuticals to Present at the 2016 American Association for Cancer Research Annual Meeting - [at noodls] - ROCKVILLE, Md., April 13, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of cancer, ...
04/12/16 06:04 PMRexahn Pharmaceuticals, Inc. (RNN) Latest Broker Coverage - Risers & Fallers - Rexahn Pharmaceuticals, Inc. (RNN) Latest Broker CoverageRisers & FallersA number of investment brokers have recently updated their price targets on shares of Rexahn Pharmaceuticals, Inc. (RNN). According to the latest broker reports outstanding on Tuesday 12th of April, 1 analyst has a rating of “strong buy”, 2 analysts ...and more »
04/11/16 05:54 PMRexahn Pharmaceuticals, Inc. (RNN) Sees Large Increase in Short Interest - Washington News Wire - Washington News WireRexahn Pharmaceuticals, Inc. (RNN) Sees Large Increase in Short InterestWashington News WireRexahn Pharmaceuticals logo Rexahn Pharmaceuticals, Inc. (NYSE:RNN) was the target of a significant increase in short interest during the month of March. As of March 31st, there was short interest totalling 1,195,343 shares, an increase of 12.8% from ...and more »
04/10/16 05:39 PMAfter Last Week What Do Analysts Think Of Rexahn Pharmaceuticals, Inc. (RNN) - Share Trading News - After Last Week What Do Analysts Think Of Rexahn Pharmaceuticals, Inc. (RNN)Share Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Rexahn Pharmaceuticals, Inc. (RNN). The latest reports which are currently in issue on Sunday 10th of April state 1 analyst has a rating of “strong buy”, 2 analysts “buy ...
04/09/16 04:31 AMRexahn Pharmaceuticals Incorporated (NYSEMKT:RNN) Shorts Decreased by 22.09% After Short Covering - Clinton Financial - Rexahn Pharmaceuticals Incorporated (NYSEMKT:RNN) Shorts Decreased by 22.09% After Short CoveringClinton FinancialThe short interest to Rexahn Pharmaceuticals Incorporated's float is 0.66%. The stock decreased 1.65% or $0.005 on April 8, hitting $0.327. About 210,146 shares traded hands. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) has declined 41.07% since ...
04/08/16 11:24 PMNew Analyst Ratings On Rexahn Pharmaceuticals, Inc. (RNN) - Risers & Fallers - New Analyst Ratings On Rexahn Pharmaceuticals, Inc. (RNN)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Rexahn Pharmaceuticals, Inc. (RNN). The latest broker reports which are currently outstanding on Friday 8th of April state 1 analyst has a rating of “strong buy”, 2 ...and more »
04/06/16 08:42 AMRexahn Pharmaceuticals, Inc. (RNN) Analyst Review - Risers & Fallers - Rexahn Pharmaceuticals, Inc. (RNN) Analyst ReviewRisers & FallersA number of investment brokers have recently updated their price targets on shares of Rexahn Pharmaceuticals, Inc. (RNN). According to the latest broker reports outstanding on Wednesday 6th of April, 1 analyst has a rating of “strong buy”, 2 analysts ...
04/04/16 11:06 PMRexahn Pharmaceuticals Incorporated (NYSEMKT:RNN) Shorted Shares Decreased By 22.09% - Stock Caller - Rexahn Pharmaceuticals Incorporated (NYSEMKT:RNN) Shorted Shares Decreased By 22.09%Stock CallerThe short interest to Rexahn Pharmaceuticals Incorporated's float is 0.66%. The stock increased 1.18% or $0.004 on April 4, hitting $0.336. About 287,899 shares traded hands. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) has declined 36.54% since ...
04/04/16 09:45 AMCompany Shares of Rexahn Pharmaceuticals (NYSEMKT:RNN) Rally 5.3% - Street Edition - Company Shares of Rexahn Pharmaceuticals (NYSEMKT:RNN) Rally 5.3%Street EditionStocks of Rexahn Pharmaceuticals (NYSEMKT:RNN) rallied by 5.3% during the past week but lost 12.25% on a 4-week basis. The company has outperformed the S&P 500 by 3.43% in the past week but underperformed the index by 15.33% in the last 4 ...
04/01/16 05:55 PMLatest Analyst Reports On Rexahn Pharmaceuticals, Inc. - Risers & Fallers - Latest Analyst Reports On Rexahn Pharmaceuticals, Inc.Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Rexahn Pharmaceuticals, Inc. (RNN). The latest broker reports which have been released state 1 analyst has a rating of “buy”, 2 analysts “outperform”, 0 analysts “hold”, ...
03/31/16 09:21 AMRexahn Pharmaceuticals Incorporated (NYSEMKT:RNN) Sellers Covered 22.09% of Their Shorts - Clinton Financial - Rexahn Pharmaceuticals Incorporated (NYSEMKT:RNN) Sellers Covered 22.09% of Their ShortsClinton FinancialRexahn Pharmaceuticals, Inc. is a clinical stage biopharmaceutical firm dedicated to the discovery, development and commercialization of treatments for cancer and other medical needs. The company has a market cap of $75.38 million. The Firm has three ...
03/28/16 05:30 PMRexahn Pharmaceuticals, Inc. (RNN) Earns “Buy” Rating from FBR & Co. - MicroCap Magazine - MicroCap MagazineRexahn Pharmaceuticals, Inc. (RNN) Earns “Buy” Rating from FBR & Co.MicroCap MagazineRexahn Pharmaceuticals logo Rexahn Pharmaceuticals, Inc. (NYSE:RNN)'s stock had its “buy” rating reaffirmed by analysts at FBR & Co. in a research note issued on Sunday, Market Beat Ratings reports. Rexahn Pharmaceuticals (NYSE:RNN) traded up ...Rexahn Pharma Receives an Outperform from FBR CapitalAnalyst Ratingsall 2 news articles »
03/25/16 09:16 AMPrice Target Update: Rexahn Pharmaceuticals (RNN) - SCSUCollegian - Price Target Update: Rexahn Pharmaceuticals (RNN)SCSUCollegianThe company has a market cap of $71 million and the number of outstanding shares have been calculated to be 213,113,790 shares. The 52-week high of Rexahn Pharmaceuticals (NYSEMKT:RNN) is $0.813 and the 52-week low is $0.26. Rexahn ...and more »
03/25/16 09:16 AMRexahn Pharma (RNN) Announces Additional Data on Supinoxin for Treating Triple Negative Breast Cancer at TAT - StreetInsider.com - Rexahn Pharma (RNN) Announces Additional Data on Supinoxin for Treating Triple Negative Breast Cancer at TATStreetInsider.comRexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) announced today that additional data supporting the Company's novel, investigational anti-cancer therapeutic, Supinoxin™ (RX-5902), for the treatment of triple negative breast cancer, were presented at the ...Rexahn Pharma Offers Added Data for Supinoxin for Treatment of Triple Negative Breast CancerBenzingaRexahn Pharmaceuticals Presents Additional Data for Supinoxin for the Treatment of Triple Negative Breast Cancer at ...Nasdaqall 3 news articles »
03/24/16 09:39 AMRexahn Pharma Offers Added Data for Supinoxin for Treatment of Triple Negative Breast Cancer - Benzinga - Rexahn Pharma Offers Added Data for Supinoxin for Treatment of Triple Negative Breast CancerBenzingaRexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of cancer, announced today that additional data supporting the Company's novel, investigational ...Rexahn Pharma (RNN) Announces Additional Data on Supinoxin for Treating Triple Negative Breast Cancer at TATStreetInsider.comRexahn Pharmaceuticals Presents Additional Data for Supinoxin for the Treatment of Triple Negative Breast Cancer at ...EconoTimesall 4 news articles »
03/24/16 08:34 AMRexahn Pharma Offers Added Data for Supinoxin for Treatment of Triple Negative Breast Cancer - Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of cancer, announced today that additional data supporting the Company's novel, investigational anti-cancer therapeutic, Supinoxin™ (RX-5902), for the treatment of triple negative breast cancer, were presented at the 14th Annual Targeted Anticancer Therapeutics Congress (TAT 2016), held in Washington, DC March 21- 23, 2016. In an oral presentation entitled "Novel Targeted Phosphorylated p68 Inhibitor, RX-5902 (Supinoxin), Shows Activity in Triple-Negative Breast Cancer," Rexahn's collaborators at the University of Colorado, School of Medicine, delivered an overview of recent findings from the Supinoxin program further elucidating its novel cancer-cell specific mechanism of action and showing potent activity in various preclinical models of triple negative breast cancer (TNBC). "The nonclinical data for Supinoxin – along with human pharmacokinetic data from the ongoing Phase I study, provides valuable evidence from which to best inform our selection of a recommended Phase II dose for further evaluation of Supinoxin," said Dr. Ely Benaim, Chief Medical Officer for Rexahn. "Collectively, ...Full story available on Benzinga.com
03/24/16 08:10 AMRexahn Pharmaceuticals Presents Additional Data for Supinoxin for the Treatment of Triple Negative Breast Cancer at the 2016 Targeted Anticancer Therapeutics Congress - [at noodls] - ROCKVILLE, Md., March 24, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of cancer, ...
03/23/16 05:43 PMNew Price Targets On Rexahn Pharmaceuticals, Inc. (RNN) - Risers & Fallers - New Price Targets On Rexahn Pharmaceuticals, Inc. (RNN)Risers & FallersRecently stock market analysts have updated their consensus ratings on shares of Rexahn Pharmaceuticals, Inc. (RNN). The latest broker reports which are currently outstanding on Wednesday 23rd of March state 1 analyst has a rating of “strong buy”, ...
03/22/16 05:38 PMRexahn Pharmaceuticals, Inc. (RNN) New Analyst Ratings - Share Trading News - Rexahn Pharmaceuticals, Inc. (RNN) New Analyst RatingsShare Trading NewsMarket analysts have recently updated their ratings and price targets on shares of Rexahn Pharmaceuticals, Inc. (RNN). The latest reports which are currently in issue on Tuesday 22nd of March state 1 analyst has a rating of “strong buy”, 2 analysts ...
03/21/16 09:05 AMRexahn Pharmaceuticals Incorporated (NYSEMKT:RNN) Shorted Shares Increased 9.88% After Market Selling - RiversideGazette.com - Rexahn Pharmaceuticals Incorporated (NYSEMKT:RNN) Shorted Shares Increased 9.88% After Market SellingRiversideGazette.comAbout 492,120 shares traded hands or 34.57% up from the average. Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) has declined 43.86% since August 13, 2015 and is downtrending. It has underperformed by 42.24% the S&P500. Rexahn Pharmaceuticals ...Company Shares of Rexahn Pharmaceuticals (NYSEMKT:RNN) Drops by -11.52%Everything HUDSONShining on Major News: Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), United Technologies Corporation (NYSE ...Stock Transcriptall 3 news articles »
03/20/16 05:42 PMCompany Shares of Rexahn Pharmaceuticals (NYSEMKT:RNN) Drops by -11.52% - Everything HUDSON - Company Shares of Rexahn Pharmaceuticals (NYSEMKT:RNN) Drops by -11.52%Everything HUDSONRexahn Pharmaceuticals (NYSEMKT:RNN) has tumbled 11.52% during the past week and has dropped 12.23% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 12.7%. Rexahn Pharmaceuticals ...
03/18/16 05:57 PMAnalyst Rating on Rexahn Pharmaceuticals (NYSEMKT:RNN) - Everything HUDSON - Analyst Rating on Rexahn Pharmaceuticals (NYSEMKT:RNN)Everything HUDSONRexahn Pharmaceuticals (NYSEMKT:RNN) has received a short term rating of buy from experts at Zacks with a rank of 2. The stock has been rated an average of 1 by 3 Brokerage Firm. 3 Wall Street Firms have rated the stock as a strong buys. Rexahn ...
03/18/16 05:57 PMRexahn Pharmaceuticals, Inc. (RNN) Updated Price Targets - Share Trading News - Rexahn Pharmaceuticals, Inc. (RNN) Updated Price TargetsShare Trading NewsRecently analysts working for a variety of stock market brokerages have changed their consensus ratings and price targets on shares of Rexahn Pharmaceuticals, Inc. (RNN). The most recent broker reports which have been released note that 1 analyst has a ...and more »
03/17/16 12:04 PMREXAHN PHARMACEUTICALS, INC. Financials -
03/15/16 05:33 PMRexahn Pharmaceuticals, Inc. (RNN) New Analyst Updates - Risers & Fallers - Rexahn Pharmaceuticals, Inc. (RNN) New Analyst UpdatesRisers & FallersA number of investment brokers have recently updated their price targets on shares of Rexahn Pharmaceuticals, Inc. (RNN). According to the latest broker reports outstanding on Tuesday 15th of March, 1 analyst has a rating of “strong buy”, 2 analysts ...and more »
03/14/16 06:08 PMWatch List: Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), Inovio Pharmaceuticals, Inc. (NASDAQ:INO), Bristol-Myers ... - KC Register - Watch List: Rexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), Inovio Pharmaceuticals, Inc. (NASDAQ:INO), Bristol-Myers ...KC RegisterRexahn Pharmaceuticals, Inc. (NYSEMKT:RNN) provides an detailed overview of Rexahn Pharmaceuticals, Inc.scenario. Report includes top line data relating on Rexahn Pharmaceuticals, Inc. Global clinical trials scenario. On Friday Rexahn ...and more »
03/14/16 06:08 PMCompany Update (NYSEMKT:RNN): Rexahn Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2015 ... - Smarter Analyst - Company Update (NYSEMKT:RNN): Rexahn Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2015 ...Smarter AnalystRexahn Pharmaceuticals, Inc. (NYSEMKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced financial results for the fourth quarter and fiscal year ended December 31, 2015 ...Rexahn Pharmaceuticals Narrows 2015 Loss vs Year Ago Level (NYSEMKT:RNN)Sonoran Weekly ReviewWhat to Expect from Rexahn Pharmaceuticals, Inc. (RNN) Earnings Per Share?Clinton FinancialRexahn Pharmaceuticals Inc.: Rexahn Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Financial ResultsThe Wall Street TranscriptMoney Morningall 8 news articles »

Social

About Rexahn Pharmaceuticals

Rexahn Pharmaceuticals logoRexahn Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery, development and commercialization of treatments for cancer. The Company's clinical-stage drug candidates in active development include Archexin, RX-3117 and Supinoxin (RX-5902). Archexin is a potent inhibitor of the protein kinase Akt-1, which focuses on cancer cell proliferation, survival, angiogenesis, metastasis and drug resistance. RX-3117 is a small molecule nucleoside compound with an anti-metabolite mechanism of action and has therapeutic potential in a range of cancers, including pancreatic, bladder, colon and lung cancer. Supinoxin is a small molecule inhibitor of phosphorylation of p68. The Company also has a drug candidate RX-21101, an N-(2-Hydroxypropyl) methacrylamide-docetaxel-folate, in pre-clinical development. The Company is working on research technologies, including multi-target aimed ligands platform and nano-based drug delivery systems.

Industry, Sector and Symbol:
  • Sector: N/A
  • Industry: N/A
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: RNN
  • CUSIP:
Key Metrics:
  • Previous Close: $0.26
  • 50 Day Moving Average: $0.2614
  • 200 Day Moving Average: $0.3104
  • P/E Ratio: N/A
  • P/E Growth: 0.0000
  • Market Cap: $55.96M
  • Current Year EPS Consensus Estimate: $-0.0900 EPS
  • Next Year EPS Consensus Estimate: $-0.0200 EPS
Additional Links:
Rexahn Pharmaceuticals (NYSE:RNN) Chart for Friday, July, 29, 2016